XML 106 R69.htm IDEA: XBRL DOCUMENT
v3.25.1

Corporate and Group Information - Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies (Details) | 12 Months Ended
--- | ---
Dec. 31, 2024
Alpine Bioscience Ltd. (“Alpine BVI”) [Member] |  |
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items] |  |
Date and place of incorporation / registration and place of operations | British Virgin Islands 8 January 2018 |
Issued ordinary share/ registered capital | One share of par value $1 |
Percentage of equity attributable to the Company Direct and Indirect | 100.00% |
Principal activities | Investment holding |
Adlai Nortye USA Inc (“Adlai US”) [Member] |  |
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items] |  |
Date and place of incorporation / registration and place of operations | The United States 30 January 2018 |
Issued ordinary share/ registered capital | 10,000 shares of par value $0.0001 each |
Percentage of equity attributable to the Company Direct and Indirect | 100.00% |
Principal activities | Clinical studies and testing, and technology development and transfer |
Adlai Nortye (Switzerland) AG (“Adlai Swiss”) [Member] |  |
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items] |  |
Date and place of incorporation / registration and place of operations | Switzerland 21 June 2022 |
Issued ordinary share/ registered capital | 100 shares of par value CHF1’000 each |
Percentage of equity attributable to the Company Direct and Indirect | 100.00% |
Principal activities | Investment holding |
Adlai Nortye PTE.LTD (“Adlai SGP”) [Member] |  |
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items] |  |
Date and place of incorporation / registration and place of operations | Singapore 22 April 2022 |
Issued ordinary share/ registered capital | Two shares of par value $1 |
Percentage of equity attributable to the Company Direct and Indirect | 100.00% |
Principal activities | Investment holding |
Adlai Nortye (HK) Limited (“Adlai HK”) [Member] |  |
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items] |  |
Date and place of incorporation / registration and place of operations | Hong Kong 24 April 2018 |
Issued ordinary share/ registered capital | HKD 0.001 |
Percentage of equity attributable to the Company Direct and Indirect | 100.00% |
Principal activities | Investment holding |
Adlai Nortye Biopharma Co., Ltd* (“Adlai Hangzhou”) [Member] |  |
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items] |  |
Date and place of incorporation / registration and place of operations | the People’s Republic of China (“PRC”)/Mainland China 14 September 2004 |
Issued ordinary share/ registered capital | RMB 200,000 |
Percentage of equity attributable to the Company Direct and Indirect | 100.00% |
Principal activities | Product research and development, technology transfer and consulting services business |
Shanghai Adlai Nortye Biopharma Co., Ltd* (“Adlai Shanghai”) [Member] |  |
Schedule of Direct and Indirect Interests in its Subsidiaries, all of Which are Private Limited Liability Companies [Line Items] |  |
Date and place of incorporation / registration and place of operations | the People’s Republic of China (“PRC”)/Mainland China 22 December 2021 | [1]
Issued ordinary share/ registered capital | RMB 10,000 | [1]
Percentage of equity attributable to the Company Direct and Indirect | 100.00% | [1]
Principal activities | Product research and development, technology transfer and consulting services business | [1]
[1] | The English name of the subsidiary registered in the PRC represents the best efforts made by management of the Company to translate its Chinese name as the subsidiary does not have an official English name.

X
- Definition Issued ordinary share, registered capital. + References No definition available. + Details
Name: | anl_IssuedOrdinaryShareRegisteredCapital
Namespace Prefix: | anl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | anl_ScheduleOfDirectAndIndirectInterestsInItsSubsidiariesAllOfWhichArePrivateLimitedLiabilityCompaniesLineItems
Namespace Prefix: | anl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The country in which a subsidiary of the entity is incorporated. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -Clause ii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_ii&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -Clause ii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_ii&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 12 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_b&doctype=Standard -URIDate 2024-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 19B -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The description of the nature of the entity's operations and principal activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 138 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_138_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2024-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=anl_AlpineBioscienceLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=anl_AdlaiNortyeUsaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=anl_AdlaiNortyeSwitzerlandAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=anl_AdlaiNortyePteltdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=anl_AdlaiNortyeHkLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=anl_HangzhouTangchuangWeilaiTechnolegyCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=anl_ShanghaiAdlaiNortyeBiopharmaCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |